A multi-model approach identifies ALW-II-41-27 as a promising therapy for osteoarthritis-associated inflammation and endochondral ossification

• DOI: 10.1016/j.heliyon.2024.e40871
• Publication Date: 2024-12-05T01:01:21Z
• Authors: Mauricio N. Ferra...; Raphaelle Lesage; Nicole Kops; Niamh Fahy; Fjodor T. Bekedam; Athina Chavli; Yvonne M. Bastiaa...; Liesbet Geris; Mark G. Chambers; Andrew A. Pitsill...; Roberto Narcisi; Gerjo J.V.M. van ...
• Keywords: Inflammation; Social sciences (General); H1-99; Kinase inhibitor; Q1-390; Science (General); SDG 3 - Good Health and Well-being; Virtual cell; Drug target; Author e-mails; Chondrocyte hypertrophy; Research Article

Low-grade inflammation and pathological endochondral ossification are key processes underlying the progression of osteoarthritis, the most prevalent joint disease worldwide. In this study, we employed a multi-faceted approach, integrating publicly available datasets, in silico analyses, in vitro experiments and in vivo models to identify new therapeutic candidates targeting these processes. Data mining of transcriptomic datasets identified EPHA2, a receptor tyrosine kinase associated with cancer, as being linked to both inflammation and endochondral ossification in osteoarthritis. A computational model of cellular signaling networks in chondrocytes predicted that in silico activation of EPHA2 in healthy chondrocytes increases inflammatory mediators and induces hypertrophic differentiation, a hallmark of endochondral ossification. We then evaluated the effect of EPHA2 inhibition using the tyrosine kinase inhibitor ALW-II-41-27 in cultured human chondrocytes from individuals with osteoarthritis, demonstrating significant reductions in both inflammation and hypertrophy. Additionally, systemic subcutaneous administration of ALW-II-41-27 in a mouse osteoarthritic model attenuated joint degeneration by reducing local inflammation and pathological endochondral ossification. Collectively, this study demonstrates a novel drug discovery pipeline that integrates computational, experimental, and animal models, paving the way for the development of disease-modifying treatments for osteoarthritis.